33 research outputs found
A Comprehensive Evaluation of Sdox, a Promising H2S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors
Design, Synthesis and Characterization of N-oxide-containing Heterocycles with In vivo Sterilizing Antitubercular Activity
Tuberculosis, caused by the Mycobacterium tuberculosis (Mtb), is the infectious disease
responsible for the highest number of deaths worldwide. Herein, 22 new N-oxide-
containing compounds were synthesized followed by in vitro and in vivo evaluation of
their antitubercular potential against Mtb. Compound 8 was found to be the most
promising compound, with MIC90 values of 1.10 and 6.62 ÎĽM against active and non-
replicating Mtb, respectively. Additionally, we carried out in vivo experiments to confirm
the safety and efficacy of compound 8; the compound was found to be orally bioavailable
and highly effective leading to the reduction of the number of Mtb to undetected levels in
a mouse model of infection. Microarray-based initial studies on the mechanism of action
suggest that compound 8 blocks the process of translation. Altogether, these results
indicated benzofuroxan derivative 8 to be a promising lead compound for the
development of a novel chemical class of antitubercular drugs
SCREENING FOR POTENTIAL HAZARD EFFECTS FROM MULTITARGET ANTHRACYCLINE ON THE CARDIOVASCULAR SYSTEM
ATP binding cassette (ABC) transporters can increase efflux
of clinical chemotherapeutic agents and lead to multi-drug
resistance (MDR) in cancer cells. Synthetic doxorubicins,
modified with moieties containing NO-releasing groups
(NitDOX), overcome drug resistance by nitrating critical tyrosine residues of ABC transporters. The introduction of a
NO-releasing group made NitDOX also a functionally distinct
anthracycline with pharmacologic properties widely different
from the parent drug. NitDOX, in fact, accumulates
preferentially in the mitochondria, where it affects critical
steps of mitochondrial metabolism. The development of
clinically useful MDR inhibitors remains a promising strategy
for addressing and potentially overcoming MDR. Drug safety,
however, is one of the main causes of discontinuation or
withdrawal of novel drugs and many reports indicate that
cardiovascular toxicity is a significant driver, being more
frequent, for example, than hepatotoxicity. In order to develop
novel and safe MDR inhibitors and considering the potential
use of NitDOX as innovative drugs, the aim of this study was
to characterize the mechanism of action and vascular effects
of the novel P-gp inhibitors, especially when considering the
role of NO in the regulation of vascular tone. Their effects
were compared to those of doxorubicin (DOXO) and
tariquidar, one of the most potent P-gp inhibitors. The results
demonstrated that NitDOX was less toxic than DOXO in
human endothelial cells at concentrations comparable to those
effective to exert antitumor activities and to accumulate in
drug-resistant cells. Both NitDOX and DOXO, however,
promoted similar cytotoxic and apoptotic effects in vascular
smooth muscle cells, while tariquidar was mostly inactive. In
conclusion, NitDOX is a functionally distinct anthracycline
with a more favorable toxicity profile and a better efficacy
against drug-resistant cells. In the context of earlier attempts to
use NO delivery strategies in cancer therapy, NitDOX is
worthy of further investigations in preclinical and clinical
settings